IGM Biosciences Dirección
Dirección controles de criterios 3/4
El CEO de IGM Biosciences' es Fred Schwarzer , nombrado en Jul 2010, tiene una permanencia de 13.75 años. compensación anual total es $5.32M, compuesta por 11.7% salario y 88.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.41% de las acciones de la empresa, por valor de $1.91M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 5.7 años, respectivamente.
Información clave
Fred Schwarzer
Chief Executive Officer (CEO)
US$3.2m
Compensación total
| Porcentaje del salario del CEO | 20.2% |
| Permanencia del CEO | 13.8yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 3yrs |
| Promedio de permanencia en la Junta Directiva | 5.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28
IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Feb 08IGM Biosciences reports quick assets and provides business updates
Jan 13Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares
Dec 18IGM Bio prices upsized $200M public offering
Dec 09IGM Biosciences proposes public offering
Dec 07IGM Biosciences (IGMS) Investor Presentation - Slideshow
Nov 20Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$647k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$238m |
| Jun 30 2023 | n/a | n/a | -US$234m |
| Mar 31 2023 | n/a | n/a | -US$229m |
| Dec 31 2022 | US$5m | US$622k | -US$221m |
| Sep 30 2022 | n/a | n/a | -US$219m |
| Jun 30 2022 | n/a | n/a | -US$205m |
| Mar 31 2022 | n/a | n/a | -US$185m |
| Dec 31 2021 | US$10m | US$598k | -US$165m |
| Sep 30 2021 | n/a | n/a | -US$139m |
| Jun 30 2021 | n/a | n/a | -US$115m |
| Mar 31 2021 | n/a | n/a | -US$95m |
| Dec 31 2020 | US$5m | US$530k | -US$81m |
| Sep 30 2020 | n/a | n/a | -US$72m |
| Jun 30 2020 | n/a | n/a | -US$61m |
| Mar 31 2020 | n/a | n/a | -US$53m |
| Dec 31 2019 | US$757k | US$428k | -US$43m |
| Sep 30 2019 | n/a | n/a | -US$37m |
| Jun 30 2019 | n/a | n/a | -US$34m |
| Mar 31 2019 | n/a | n/a | -US$27m |
| Dec 31 2018 | US$519k | US$376k | -US$23m |
Compensación vs. Mercado: La compensación total de Fred($USD5.32M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.37M).
Compensación vs. Ingresos: La compensación de Fred ha sido consistente con los resultados de la empresa en el último año.
CEO
Fred Schwarzer (70 yo)
13.8yrs
Permanencia
US$3,207,328
Compensación
Mr. Fred M. Schwarzer, J.D., was a Founder of Charter Life Sciences, a venture capital firm specializing in life sciences investments, in 2003 and served as its Managing Partner from inception until August...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 13.8yrs | US$3.21m | 0.41% $ 2.3m | |
| Chief Scientific Officer | 11.7yrs | US$1.57m | 0.18% $ 974.8k | |
| Chief Medical Officer | 2.8yrs | US$1.56m | 0.038% $ 208.7k | |
| Chief Financial Officer | 5.3yrs | US$1.08m | 0.031% $ 171.3k | |
| Senior Vice President of Group Operations | 1.3yrs | sin datos | sin datos | |
| Senior VP | 2.1yrs | sin datos | 0.0020% $ 11.2k | |
| Senior Vice President of Legal Affairs | 3.3yrs | sin datos | sin datos | |
| Chief Human Resources Officer | 4.8yrs | sin datos | sin datos | |
| Senior Vice President of Immuno-Oncology | 2.7yrs | sin datos | sin datos | |
| Chief Business Officer | 3.1yrs | US$4.92m | 0.028% $ 153.4k | |
| Executive Vice President of Process Development & Manufacturing | 3yrs | sin datos | sin datos | |
| Head of Research & Autoimmunity | 2.5yrs | sin datos | 0.15% $ 815.9k |
3.0yrs
Permanencia media
58.5yo
Promedio de edad
Equipo directivo experimentado: IGMS's management team is considered experienced (3 years average tenure).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 21.2yrs | US$3.21m | 0.41% $ 2.3m | |
| Independent Director | 3.3yrs | US$168.55k | 0.0038% $ 20.8k | |
| Independent Director | 5.3yrs | US$178.30k | 0.68% $ 3.8m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.8yrs | US$166.09k | 0.0099% $ 55.0k | |
| Independent Director | 5.7yrs | US$166.09k | 0.14% $ 797.6k | |
| Independent Director | 5.7yrs | US$204.09k | 0.0034% $ 18.8k | |
| Independent Director | 5.7yrs | US$175.84k | 0.091% $ 502.0k | |
| Independent Director | 5.7yrs | US$236.59k | 0% $ 0 | |
| Independent Director | less than a year | US$167.54k | 0.0025% $ 13.6k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
5.7yrs
Permanencia media
54yo
Promedio de edad
Junta con experiencia: La junta directiva de IGMS se considera experimentada (5.7 años de antigüedad promedio).